Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, response, and...

詳細記述

保存先:
書誌詳細
出版年:Hemasphere
主要な著者: Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.
フォーマット: Artigo
言語:Inglês
出版事項: Wolters Kluwer Health 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306303/
https://ncbi.nlm.nih.gov/pubmed/32647793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000363
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料